Presentation of Half Year 2025 report with focus on business update and outlook

Are you planning similar data release as for Southcare also for Majesticare and Parkhome? When can we expect update on whether the last two will expand their initial pilot programs to their full groups?

Getting a new product out on market is very challenging, perhaps particularly so in health-care. What typical conversion rates do you expect from now until mid next year? Please use a metric of your convenience for this (e.g., fraction of initial contacts that become contracts, or something similar).

The pressrelease today showed remarkably good first results. Do you believe these will have a practical impact also on the execution of your planned roll-out already this fall? And within a 12 month period, what other factors do you believe will be key for various groups of care-homes when they ultimately decide whether to give Ayla a chance or not?

As the CEO of a thriving company like Brain+, is Devika Wood fully focused on Brain+? Does she perhaps have any side projects that might prevent her from dedicating her full efforts to the company?

You have previously stated, and continue to maintain, that you will reach breakeven before running out of financial resources in mid-’26. Have you already made contingency plans in case this target is not met, meaning that another capital raise — and potentially further dilution of the shares — would be necessary?

Yesterday you released a pilot project on the effect of Ayla and CST together with South Care Homes, which shows some promising results. What are your plans for further research, particularly studies that lean more towards the quantitative field in the near future?

Dear Brainers - can you elaborate on the workload within B+ - is staff sufficiant to execute on your plans or are you too less people to reach out for all potentials ? looking forward to the updating webinar :-)

Brain+ have increased the potential output from the 3 care centers, from 310t DKK, to 450t DKK. Why is that?

You have lowered the expected payments, from to 3.0 million DKK for 2025, with the reason, longer cycluses between contracts and payments. How common a problem is that, and why is that problem existing at all?

Have Brain+ since the last webinar, received interests in Ayla from entities/care homes, that Brain+ have not been reaching out to, before they reached out to Brain+, with an interest in Ayla?

Can you confirm, that Brain+'s pipeline value, and possible contracts, have increased 7-fold, since the webinar in june 2025?

Can you provide an update on the status of your EIC Accelerator application – was it submitted for the March deadline this year, and what are the next steps in the process? In addition, are you pursuing funding from other sources, and could such funds be realized before the expected break-even in H2 2026?